Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Jen Fang

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Gastroenterology|July 3, 2018
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori InfectionJyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, et al.
Plos One|May 6, 2015
The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide StudyJyh-Ming Liou, Chi-Yang Chang, Mei-Jyh Chen, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2012
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Lancet (London, England)|November 20, 2012
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Mei-Jyh Chen, et al.
Helicobacter|July 18, 2022
Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysisMei-Jyh Chen, Ming-Jong Bair, Po-Yueh Chen, et al.
The Lancet. Infectious Diseases|September 28, 2019
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chih-Min Chang, et al.
The American Journal of Gastroenterology|February 3, 2016
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized TrialJyh-Ming Liou, Ming-Jong Bair, Chieh-Chang Chen, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2023
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trialsMei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
Gastroenterology|July 3, 2018
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori InfectionJyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, et al.
Plos One|May 6, 2015
The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide StudyJyh-Ming Liou, Chi-Yang Chang, Mei-Jyh Chen, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2012
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Lancet (London, England)|November 20, 2012
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Mei-Jyh Chen, et al.
Helicobacter|July 18, 2022
Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysisMei-Jyh Chen, Ming-Jong Bair, Po-Yueh Chen, et al.
The Lancet. Infectious Diseases|September 28, 2019
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chih-Min Chang, et al.
The American Journal of Gastroenterology|February 3, 2016
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized TrialJyh-Ming Liou, Ming-Jong Bair, Chieh-Chang Chen, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2023
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trialsMei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, et al.
Pageof 5